Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

CopyBet review JAK1 inhibitor GVHD phase III clinical trial failed Gelesis Secures Over $84 Million in New Funding to Support Commercialization of PLENIT ...

fantasy cricket expert Strategies for the development of new drugs for graft-versus-host disease (GVHD) $100 million! Hausen Pharmaceuticals licenses EQRx to acquire rights to Ametinib outside China ...

INR:4950. january 2023 ka satta king Academician Chen Wei: The Chinese virus "hunter" who "strikes back" in retrograde HEC Pharmaceutical's "Recombinan ...

INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...

INR:8172. mobile app Roche releases new data from two-year study of risdiplam in infants, children and adults with SMA Shengde's diabetes drug candidate CS02 Phase II ...

INR:5558. rummy star 3 patti Nature review: New force in cancer immunotherapy - NK cell therapy Strategies for the development of new drugs for graft-versus-ho ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Meiji Seika Pharma announced the establishment of a local subsidiary, "Taiwan Meiji Pharma Co., Ltd." (Headquarters: Taipei ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!